Phoenix Molecular Designs Expands PMD-026 into Second Clinical Indication with Myelofibrosis Trial at WashU Medicine

SAN DIEGO, California – VANCOUVER, British Columbia, May 27, 2026 – Phoenix Molecular Designs (PhoenixMD), a clinical-stage precision oncology company developing first-in-class RSK kinase inhibitors, today announced the expansion of its lead asset PMD-026 into a second clinical indication with the initiation of Dauntless-3, an investigator-initiated Phase 1 trial in myelofibrosis at Washington University School of Medicine in St. Louis. Conducted at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, the trial extends the PMD-026 program from breast cancer into hematologic cancers.